+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection



Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection



Transplantation 55(3): 677-679




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032987742

Download citation: RISBibTeXText

PMID: 8456493


Related references

Pentoxifylline does not prevent cytokine induced first dose reactions following therapy of acute renal transplant rejection with OKT3. Nephrology Dialysis Transplantation 10(6): 1070, 1995

Pure anti t cell therapy okt3 may fail to reverse acute rejection of a cadaveric renal transplant. Kidney International 33(1): 447, 1988

High or low dose steroid therapy for acute renal transplant rejection after prophylactic OKT3 treatment: a prospective randomized study. Transplant International 5(Suppl. 1): S437-S439, 1992

High or low dose steroid therapy for acute renal transplant rejection after prophylactic Okt3 treatment: a prospective randomized study. Transplant International 5: S437-S439, 1992

Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients. Transplantation Proceedings 30(2): 285-287, 1998

Uveitis associated with OKT3 therapy for renal transplant rejection. British Journal of Ophthalmology 85(4): 500-501, 2001

Concomitant low-dose cyclosporine and OKT3 therapy for renal transplant rejection. Transplantation Proceedings 21(1 Pt 2): 1755-1757, 1989

The use of outpatient OKT3 for renal transplant rejection is both cost-effective and safe as compared to inpatient OKT3 use. Clinical & Investigative Medicine 20(4 Suppl. ): S106, 1997

Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. International Journal of Radiation Oncology Biology Physics 34(5): 1055-1059, 1996

Diffuse anterior scleritis during OKT3 monoclonal antibody therapy for renal transplant rejection. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie 27(1): 22-24, 1992

Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients. Transplantation Proceedings 28(3): 1354-1355, 1996

Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation 50(5): 776-782, 1990

Orthoclone OKT3 as first-line therapy in acute renal allograft rejection. Transplantation Proceedings 22(1): 219-220, 1990

Primary therapy with OKT3 for biopsy-proven acute renal allograft rejection. Transplantation Proceedings 30(4): 1178-1180, 1998

Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody. Journal of International Medical Research 19(5): 419-423, 1991